Capmaxen (Capmatinib) 200mg

Capmaxen (Capmatinib) 200mg

Capmaxen 200mg contains Capmatinib, a targeted anticancer medicine used to treat non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. Capmatinib works by blocking abnormal MET signaling, reducing tumor growth and slowing disease progression.

Field Details
Original Brand Tabrecta
Generic Brand Capmaxen 200
Generic Name Capmatinib 200mg
Pack Size 56 Tablets
Use / Indications MET Exon 14 Skipping Mutation-Positive NSCLC
Manufacturer Everest Pharmaceuticals Ltd. (Produced in Bangladesh)
Status Prescription Only Medicine

Introduction to Tabrecta (Capmatinib) 200mg

Tabrecta (Capmatinib) 200mg is a prescription medicine used in the treatment of advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations. This medicine belongs to a specialized group of targeted oncology drugs that work by blocking abnormal MET signaling pathways, which are responsible for tumor growth and spread.

Tabrecta (Capmatinib) 200mg is classified under Prescription Medicines, Oncology Medicines, Anticancer Drugs, and Targeted Cancer Therapies. It contains Capmatinib, which specifically inhibits MET receptor tyrosine kinase involved in cancer progression.

In some markets, Capmaxen 200mg is available as a generic brand containing the same active ingredient Capmatinib, offering a similar therapeutic effect when prescribed by a qualified healthcare professional.

What Is Tabrecta (Capmatinib)?

Tabrecta is the original brand name for Capmatinib, an oral medication used for the treatment of advanced NSCLC with MET exon 14 skipping mutations.

Capmatinib belongs to a class of medicines known as MET inhibitors, a type of targeted therapy designed to block abnormal signaling in cancer cells.

Generic versions such as Capmaxen 200mg contain the same active compound and may be used depending on physician recommendation and regional availability.

Drug Class and Mechanism of Action

Capmatinib is classified as a MET tyrosine kinase inhibitor with strong antineoplastic and targeted therapy properties.

How Capmatinib Works

It works in several ways:

  • Inhibits MET receptor tyrosine kinase that promotes tumor growth
  • Blocks abnormal cell signaling pathways in cancer cells
  • Slows tumor progression and spread

Through these mechanisms, Capmatinib helps control NSCLC with MET exon 14 skipping mutations.

How Tabrecta Works in the Body

Certain lung cancers develop due to MET exon 14 skipping mutations that drive uncontrolled cell growth. Tabrecta selectively targets these mutations to inhibit cancer progression.

Key Actions of Capmatinib

  • Blocks MET signaling pathways in cancer cells
  • Reduces tumor cell proliferation
  • Helps slow disease progression in mutation-positive NSCLC

Some generic versions such as Capmaxen deliver the same active compound, allowing similar targeted therapy when prescribed appropriately.

Medical Uses of Tabrecta (Capmatinib) 200mg

Tabrecta 200mg is prescribed for advanced NSCLC patients with MET exon 14 skipping mutations.

Tabrecta for NSCLC with MET Exon 14 Skipping Mutations

For patients with previously treated or metastatic NSCLC harboring MET exon 14 skipping mutations, Tabrecta is used as targeted therapy.

Potential Benefits

  • Specifically targets MET exon 14 skipping mutations
  • Slows tumor progression
  • May improve clinical outcomes in selected patients

Generic alternatives like Capmaxen 200mg may also be used under medical supervision when Capmatinib therapy is recommended.

Who Can Take Capmaxen 200mg?

Because Capmatinib is a potent targeted therapy, treatment should always be supervised by an experienced healthcare provider.

Eligibility Criteria

Patients may be prescribed Tabrecta if they:

  • Have confirmed MET exon 14 skipping mutation-positive NSCLC
  • Are diagnosed with advanced or metastatic NSCLC
  • Have received prior systemic therapy or are not candidates for standard treatments

Certain generic options such as Capmaxen may also be considered depending on availability and physician decision.

Who Should Avoid Tabrecta (Capmatinib) 200mg

Tabrecta should NOT be used by:

  • Individuals with hypersensitivity to Capmatinib
  • Patients with severe liver or kidney impairment without supervision
  • Individuals with serious heart or lung conditions unless monitored by a specialist

Tabrecta (Capmatinib) 200mg Dosage and Administration

Standard Dosage Guidelines

Typical dosage recommendations include:

  • Tabrecta 200mg orally twice daily
  • Tablets should be swallowed whole with water
  • Can be taken with or without food
  • Treatment continues as long as clinical benefit is observed

Dosage Adjustments

Doctors may adjust the dose depending on:

  • Liver and kidney function
  • Severity of side effects
  • Individual response to therapy

Side Effects of Tabrecta 200mg

Like all cancer medicines, Tabrecta may cause side effects.

Common Side Effects

  • Swelling of hands, feet, or face (edema)
  • Nausea or vomiting
  • Fatigue
  • Shortness of breath

Serious Side Effects

Liver Toxicity: Elevated liver enzymes requiring monitoring
Interstitial Lung Disease (ILD): Rare lung inflammation
Heart Problems: Rare arrhythmias or cardiac events

Patients should report any unusual symptoms to their doctor immediately.

Storage:
Store below 25°C in a cool, dry place, protected from moisture and direct sunlight. Keep the tablets in their original packaging and out of reach of children.

Frequently Asked Questions (FAQs)

1. What is Tabrecta (Capmatinib) 200mg used for?

Tabrecta is used to treat advanced non-small cell lung cancer with MET exon 14 skipping mutations.

2. Is Capmatinib chemotherapy?

No. Capmatinib is a targeted therapy that blocks specific MET signaling pathways rather than using traditional chemotherapy.

3. Can Capmatinib cure lung cancer?

Capmatinib is not a cure but helps control tumor growth and slow disease progression in eligible patients.

4. How is MET exon 14 mutation detected?

Doctors perform genetic or molecular testing on tumor tissue to identify MET exon 14 skipping mutations.

5. Is Capmaxen 200mg the same as Tabrecta?

Capmaxen 200mg contains Capmatinib, the same active ingredient found in Tabrecta. Generic versions is available. for more info. contact on WhatsApp: https://wa.me/8801742433764

6. Do I need a prescription to buy Capmaxen (Capmatinib) 200mg?

Yes. Capmaxen 200mg is a prescription-only medicine and should only be used under the supervision of a qualified healthcare professional.

Medical Disclaimer

Disclaimer:
The information provided on this page is for educational and informational purposes only and should not be considered medical advice. Tabrecta (Capmatinib) is a prescription-only medication and must be used strictly under the supervision of a qualified healthcare professional. Always consult your physician before starting, stopping, or changing any medication.

 

Let's Chat!